Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
SlideShare a Scribd company logo

Q3 2009 Earning Report of Walgreen Co.

•
•
E
earningreport earningreport

This document provides an agenda and highlights for Walgreen Co.'s 4th quarter and fiscal year 2009 conference call with investors. It includes introductions, a discussion of 4Q and FY performance and strategies, financial results, and a Q&A session. Key metrics highlighted are 7.6% sales growth and a 1.5% decline in net earnings for 4Q, and 7.3% sales growth and a 7% decline in net earnings for FY2009. The document also outlines Walgreen's strategies around healthcare reform, the flu season, and expanding their business model.

1 of 41
4th Quarter and Fiscal Year 2009 Conference Call September 29, 2009 © Copyright 2009 Walgreen Co. 1
Fourth Quarter and Fiscal Year 2009 Agenda  Introduction Rick Hans & Safe Harbor Divisional VP - IR & Finance  4Q and FY Highlights Greg Wasson & Strategies Update President & CEO  4Q and FY Financials Wade Miquelon Executive Vice President & CFO  Questions & Answers All © Copyright 2009 Walgreen Co. 2
Safe Harbor  Certain statements and projections of future results made in this presentation f t lt d i thi t ti constitute forward-looking information that is based on current market, competitive and regulatory expectations that involve risk and uncertainty.  Please see our latest Forms 10-K and 10-Q for a discussion of factors as they relate to forward-looking statements. © Copyright 2009 Walgreen Co. 3
4Q and FY09 Highlights & Strategies Update Greg Wasson President & CEO © Copyright 2009 Walgreen Co. 4
Fourth Quarter Highlights In $ Millions except EPS 4Q08 4Q09 Change Net Sales $14,597 $15,703 7.6% Net Earnings $443 $436* (1.5%) EPS, diluted $0.45 $0.44* (2.2%) Cash From Operations $548 $852 55.5% * Includes $33 million after-tax, or $.03 per diluted share, restructuring and restructuring-related costs. © Copyright 2009 Walgreen Co. 5
Fiscal 2009 Highlights In $ Millions except EPS FY08 FY09 Change Net Sales $59,034 $63,335 7.3% Net Earnings $2,157 $2,006* (7.0%) EPS, diluted $2.17 $2.02* (6.9%) Cash From Operations $3,039 $4,111 35.3% * Includes $163 million after-tax, or $.16 per diluted share, restructuring and restructuring-related costs. © Copyright 2009 Walgreen Co. 6
On the Frontlines of Healthcare  Healthcare Reform  Support need for healthcare reform  Focus on prevention and wellness  Employer funded medical coverage critical Employer-funded  Provider of quality, affordable, accessible healthcare with 68,000 health professionals  Update on flu season  16 000 16,000 certified immunizers  Significant growth in seasonal flu shots  Positioned for H1N1 pandemic © Copyright 2009 Walgreen Co. 7
Taking Walgreen Co. to the Market Co  Platforms in place  7,000 drugstores  Specialty pharmacy and infusion  700 worksite health centers and retail clinics  Direct-to-employer/government/MCO/PBM  Caterpillar – Proprietary, transparent price list  Direct-to-consumer  Prescription Savings Club – nearly 2M members © Copyright 2009 Walgreen Co. 8
Consumers Respond to 90-Day at Retail % of 90-Day Prescriptions  Promotes choice 5.0% 4.5%  Drives adherence 4.0%  Increases compliance 3.5%  Improves outcomes 3.0% 2.5%  Lowers costs 2.0% 2005 2006 2007 2008 2009 % = (# of 90-day Rx/(# of 30-day + 90-day Rx))x100 © Copyright 2009 Walgreen Co. 9
Leveraging & Enhancing Our Core Business Slowing store openings Re-inventing the customer experience Transforming community pharmacy Expanding health & wellness Expanding specialty pharmacy Broadening & deepening g p g payor relationships Rewiring for growth © Copyright 2009 Walgreen Co. 10
Projected Net New Store Openings 12% 10% Estimated 8% 6% 3% Growth 4% 2% 0% 2007 2008 2009 2010 2011 New store openings include new and relocated stores © Copyright 2009 Walgreen Co. 11
SG&A Growth Declining Ahead of Slowing Store Growth Store Added (including On-Site and 700 25% e Walgreen Rx Only stores) 600 20% 500 SG&A Growth Rate y 400 15% 300 10% ns 200 5% 100 es 0 0% FY99 FY00 FY01 FY02 FY03 FY04 FY05 FY06 FY07 FY08 FY09 Organic g Acquired q Adjusted for restructuring and restructuring-related costs © Copyright 2009 Walgreen Co. 12
Reinventing the Customer Experience  4Q09 Milestones – Rolling out CCR in 400 Texas stores – Rolling out convenience offering of beer and wine – Re launched walgreens com Re-launched walgreens.com 2008 2009 2010 3Q09 – Apr/May Fall ’09 – Sep/Oct 09 Calendar 2010  35-store CCR pilot  CCR rollout in TX markets  CCR rollout nationwide  Category optimization  Begin beer and wine rollout  Loyalty initiative pilot  Inventory improvements  Re-launched Walgreens.com © Copyright 2009 Walgreen Co. 13
the new walgreens com walgreens.com © Copyright 2009 Walgreen Co. 14
Cost Reductions & Productivity Gains Year-over-Year Percent Increase 20% Gross Profit 15% SG&A 10% 5% 0% 2004 2005 2006 2007 2008 2009 SG&A adjusted for restructuring and restructuring-related costs in 1Q, 2Q, 3Q and 4Q 2009 Gross Profit adjusted for restructuring and restructuring-related costs in 2Q, 3Q, and 4Q 2009 © Copyright 2009 Walgreen Co. 15
© Copyright 2009 Walgreen Co. 16
4Q and FY09 Financial Review Wade Miquelon Executive VP and CFO © Copyright 2009 Walgreen Co. 17
Fourth Quarter Highlights 4Q08 4Q09 Net Sales 8.8% 7.6% Net Earnings 11.7% (1.5%) EPS (Diluted) $0.45 $0.44* Prescriptions Sales ($) 7.9% 9.0% Total Prescriptions (#) 4.9%** 9.1%** p Comparable Prescription Sales 2.0% 4.5% Front-end Sales 3.7% (1.4%) Total Sales 2.6% 2 6% 2.4% 2 4% Rx Scripts 1.1%*** 5.9%*** *Includes $.03 per share, diluted, of restructuring and restructuring-related costs. **Includes **I l d 111 b i 4Q08 and 136 b i 4Q09 positive i bp in d bp in iti impact d t more patients filli 90 d prescriptions t due to ti t filling 90-day i ti ***Includes 118 bp in 4Q08 and 179 bp in 4Q09 positive impact due to more patients filling 90-day prescriptions © Copyright 2009 Walgreen Co. 18
Fiscal Year 2009 Highlights FY08 FY09 Net Sales 9.8% 7.3% Net Earnings 5.7% (7.0%) EPS (Diluted) $2.17 $2.02* Prescriptions Sales ($) 9.7% 7.8% Total Prescriptions (#) 6.4%** 6.9%** p Comparable Prescription Sales 3.9% 3.5% Front-end Sales 4.2% (0.5%) Total Sales 4.0% 4 0% 2.0% 2 0% Rx Scripts 2.8%*** 3.6%*** *Includes $.16 per diluted share, of restructuring and restructuring-related costs. **Includes **I l d 64 b i FY08 and 137 b i FY09 positive i bp in d bp in iti impact d t more patients filli 90 d prescriptions t due to ti t filling 90-day i ti ***Includes 75 bp in FY08 and 173 bp in FY09 positive impact due to more patients filling 90-day prescriptions © Copyright 2009 Walgreen Co. 19
Gross Profit Margin 4Q08 4Q09 Change Gross Profit Margin 27.6% 27.7% +10 bps  Margin impacts + Positively impacted by retail pharmacy margins due to generics g - Partially offset by non-retail businesses, and lower FE margins d e to prod ct mi LIFO and due product mix, restructuring and restructuring-related costs © Copyright 2009 Walgreen Co. 20
Percent Increase in SG&A Dollars Two-year Stacked 30% 28.0% 25.5% % 24.9% 25% 23.4% 10.0% 20% 11.2% 10.2% 8.0% 18.6% 16.9% 16 9% 17.6% 17 6% 15% 8.6% 14.1% 5.7% 7.4% 10% 6.1% 18.0% 18 0% 14.3% 14.7% 15.4% 5% 10.0% 11.2% 10.2% 8.0% 0% 1Q07 2Q07 3Q07 4Q07 1Q08 2Q08 3Q08 4Q08 +1Q08 +2Q08 +3Q08 +4Q08 +1Q09 +2Q09 +3Q09 +4Q09 Note: SG&A data adjusted for vacation accrual in 4Q08 and restructuring and restructuring-related costs in 1Q, 2Q, 3Q and 4Q 2009. © Copyright 2009 Walgreen Co. 21
Rewire for Growth on Target  $500 million pre-tax savings in FY10  $1 billion pre-tax savings in FY11 1Q09 2Q09 3Q09 4Q09 Savings $.01 $.02 $.06 $.07 Costs* ($.01) ($.06) ($.06) ($.03) Net $.00 ($.04) $.00 $.04 Savings *Restructuring and restructuring-related charges include impact of CCR markdown activity on gross profit margin Restructuring © Copyright 2009 Walgreen Co. 22
Income Statement Details 4Q08 4Q09 LIFO Provision $24M $48M g Restructuring $51M  SKU discontinuation $19M  Consultants and other $23M  Reduction in force $9M Net Interest Expense $7M $23M Tax Rate 37.1% 35.8% © Copyright 2009 Walgreen Co. 23
Balance Sheet Highlights 4Q08 4Q09 Change Accounts Receivable $2.5B $2.5B (1.2%) Inventories $7.2B $6.8B ( (6.3%) ) Accounts Payable ($4.3B) ($4.3B) 0.4% Total $5.4B $5 4B $5.0B $5 0B (7.4%) (7 4%) Total as a % of Sales 37.0% 31.8% 14.1% © Copyright 2009 Walgreen Co. 24
FIFO Inventory Trends 4Q08 1Q09 2Q09 3Q09 4Q09 Percent Change Total 7.2% 10.0% 4.6% (0.3%) (3.5%) Inventory I t Percent C Change Total g (2.2%) (2 2%) 0.1% 0 1% (4.0%) (4 0%) (9.1%) (9 1%) (11.1%) (11 1%) Inventory per Store* *Total FIFO inventory/total drugstore locations Total © Copyright 2009 Walgreen Co. 25
Net Cash 1Q09 2Q09 3Q09 4Q09 Cash $886 $909 $2,300 $2,087 Short Term – $650 $100 $500 Investments Short Term Debt $1,081 $12 $10 $15 Long Term Debt $1,337 $2,332 $2,338 $2,336 Net Cash* ($1,532M) ($785M) $52M $236M *Net cash = cash and cash-equivalents plus short-term investments less short-term and long-term debt © Copyright 2009 Walgreen Co. 26
Capital Expenditures Dollars in Billions FY08 FY09 FY10E New Stores $1.6 $1.4 lower Existing Stores $0.3 $0.2 higher DCs $0.1 $0 1 $0.1 $0 1 lower IT & Other $0.2 $0.2 higher Total T t l $2.2 $2 2 $1.9 $1 9 ~$1.6 $1 6 © Copyright 2009 Walgreen Co. 27
Cash Flow ($ in Millions) Cash Flow from Operations Free Cash Flow (From St t (F Statements of Cash Flows) t f C h Fl ) (FCF=Cash Flow from Operations – C E ) (FCF C h Fl f O ti CapEx) 1,500 1,500 2009 1,000 1,000 2009 2008 500 500 2008 0 0 -500 -500 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q © Copyright 2009 Walgreen Co. 28
The Road Ahead  Opportunities – Executing our 3 core strategies – Significant growth and share gain – Aggressively investing in business model  Challenges... Our Next Opportunities – Reimbursement pressure continues – Economic uncertainty © Copyright 2009 Walgreen Co. 29
Questions & Answers Q ti A © Copyright 2009 Walgreen Co. 30
© Copyright 2009 Walgreen Co. 31
Appendix © Copyright 2009 Walgreen Co. 32
Calculation of Adjusted SG&A: Restructuring Restr ct ring and Restructuring-Related Costs Restr ct ring Related Dollars in Millions 1Q08 1Q09 SGA under GAAP $ 3,193 $ 3,482 Less: Restructuring and g Restructuring-related Costs $ - $ 14 Adjusted SGA $ 3,193 $ 3,468 Adjusted YOY % Increase 8.6% © Copyright 2009 Walgreen Co. 33
Calculation of Adjusted Gross Profit: Restructuring Restr ct ring and Restructuring-Related Costs Restr ct ring Related Dollars in Millions 2Q08 2Q09 Gross Profit under GAAP $ 4,442 $ 4,657 Plus: Restructuring and g Restructuring-related Costs $ - $ 11 Adjusted Gross Profit $ 4,442 $ 4,668 Adjusted YOY % Increase 5.1% © Copyright 2009 Walgreen Co. 34
Calculation of Adjusted SG&A: Restructuring Restr ct ring and Restructuring-Related Costs Restr ct ring Related Dollars in Millions 2Q08 2Q09 SGA under GAAP $ 3,354 $ 3,627 Less: Restructuring and g Restructuring-related Costs $ - $ 82 Adjusted SGA $ 3,354 $ 3,545 Adjusted YOY % Increase 5.7% © Copyright 2009 Walgreen Co. 35
Calculation of Adjusted Gross Profit: Restructuring Restr ct ring and Restructuring-Related Costs Restr ct ring Related Dollars in Millions 3Q08 3Q09 Gross Profit under GAAP $ 4,245 $ 4,459 Plus: Restructuring and g Restructuring-related Costs $ - $ 65 Adjusted Gross Profit $ 4,245 $ 4,524 Adjusted YOY % Increase 6.6% © Copyright 2009 Walgreen Co. 36
Calculation of Adjusted SG&A: Restructuring Restr ct ring and Restructuring-Related Costs Restr ct ring Related Dollars in Millions 3Q08 3Q09 SGA under GAAP $ 3,331 $ 3,613 Less: Restructuring and g Restructuring-related Costs $ - $ 34 Adjusted SGA $ 3,331 $ 3,579 Adjusted YOY % Increase 7.4% © Copyright 2009 Walgreen Co. 37
Calculation of Adjusted Gross Profit: Restructuring Restr ct ring and Restructuring-Related Costs Restr ct ring Related Dollars in Millions 4Q08 4Q09 Gross Profit under GAAP $ 4,035 $ 4,346 Plus: Restructuring and g Restructuring-related Costs $ - $ 19 Adjusted Gross Profit $ 4,035 $ 4,365 Adjusted YOY % Increase 8.2% © Copyright 2009 Walgreen Co. 38
Calculation of Adjusted SG&A: Restructuring Restr ct ring and Restructuring-Related Costs Restr ct ring Related Dollars in Millions 4Q08 4Q09 SGA under GAAP $ 3,324 $ 3,644 Less: Restructuring and g Restructuring-related Costs $ - $ 32 Adjusted SGA $ 3,324 $ 3,612 Adjusted YOY % Increase 8.7% © Copyright 2009 Walgreen Co. 39
Reconciliation of FIFO Inventory: 4Q08 1Q09 2Q09 3Q09 4Q09 Total FIFO $8,316.3 $9,408.4 $8,742.2 $8,082.4 $8,028.7 Inventory LIFO Provision $1,067.3 $1,110.5 $1,158.7 $1,191.4 $1,239.4 O Total LIFO $7,249.0 $7 249 0 $8,297.9 $8 297 9 $7,583.5 $7 583 5 $6,891.0 $6 891 0 $6,789.3 $6 789 3 Inventory © Copyright 2009 Walgreen Co. 40
Calculation of Free Cash Flow: 1Q08 2Q08 3Q08 4Q08 1Q09 2Q09 3Q09 4Q09 Cash Flow from Operations $390 $1,116 $985 $548 $312 $1,428 $1,519 $852 under GAAP Capital Expenditures ($490) ($553) ($610) ($572) ($638) ($454) ($442) ($393) under GAAP Free Cash Flow non-GAAP ($100) $563 $375 ($24) ($326) $974 $1,077 $459 measure © Copyright 2009 Walgreen Co. 41

More Related Content

Q3 2009 Earning Report of Walgreen Co.

  • 1. 4th Quarter and Fiscal Year 2009 Conference Call September 29, 2009 © Copyright 2009 Walgreen Co. 1
  • 2. Fourth Quarter and Fiscal Year 2009 Agenda  Introduction Rick Hans & Safe Harbor Divisional VP - IR & Finance  4Q and FY Highlights Greg Wasson & Strategies Update President & CEO  4Q and FY Financials Wade Miquelon Executive Vice President & CFO  Questions & Answers All © Copyright 2009 Walgreen Co. 2
  • 3. Safe Harbor  Certain statements and projections of future results made in this presentation f t lt d i thi t ti constitute forward-looking information that is based on current market, competitive and regulatory expectations that involve risk and uncertainty.  Please see our latest Forms 10-K and 10-Q for a discussion of factors as they relate to forward-looking statements. © Copyright 2009 Walgreen Co. 3
  • 4. 4Q and FY09 Highlights & Strategies Update Greg Wasson President & CEO © Copyright 2009 Walgreen Co. 4
  • 5. Fourth Quarter Highlights In $ Millions except EPS 4Q08 4Q09 Change Net Sales $14,597 $15,703 7.6% Net Earnings $443 $436* (1.5%) EPS, diluted $0.45 $0.44* (2.2%) Cash From Operations $548 $852 55.5% * Includes $33 million after-tax, or $.03 per diluted share, restructuring and restructuring-related costs. © Copyright 2009 Walgreen Co. 5
  • 6. Fiscal 2009 Highlights In $ Millions except EPS FY08 FY09 Change Net Sales $59,034 $63,335 7.3% Net Earnings $2,157 $2,006* (7.0%) EPS, diluted $2.17 $2.02* (6.9%) Cash From Operations $3,039 $4,111 35.3% * Includes $163 million after-tax, or $.16 per diluted share, restructuring and restructuring-related costs. © Copyright 2009 Walgreen Co. 6
  • 7. On the Frontlines of Healthcare  Healthcare Reform  Support need for healthcare reform  Focus on prevention and wellness  Employer funded medical coverage critical Employer-funded  Provider of quality, affordable, accessible healthcare with 68,000 health professionals  Update on flu season  16 000 16,000 certified immunizers  Significant growth in seasonal flu shots  Positioned for H1N1 pandemic © Copyright 2009 Walgreen Co. 7
  • 8. Taking Walgreen Co. to the Market Co  Platforms in place  7,000 drugstores  Specialty pharmacy and infusion  700 worksite health centers and retail clinics  Direct-to-employer/government/MCO/PBM  Caterpillar – Proprietary, transparent price list  Direct-to-consumer  Prescription Savings Club – nearly 2M members © Copyright 2009 Walgreen Co. 8
  • 9. Consumers Respond to 90-Day at Retail % of 90-Day Prescriptions  Promotes choice 5.0% 4.5%  Drives adherence 4.0%  Increases compliance 3.5%  Improves outcomes 3.0% 2.5%  Lowers costs 2.0% 2005 2006 2007 2008 2009 % = (# of 90-day Rx/(# of 30-day + 90-day Rx))x100 © Copyright 2009 Walgreen Co. 9
  • 10. Leveraging & Enhancing Our Core Business Slowing store openings Re-inventing the customer experience Transforming community pharmacy Expanding health & wellness Expanding specialty pharmacy Broadening & deepening g p g payor relationships Rewiring for growth © Copyright 2009 Walgreen Co. 10
  • 11. Projected Net New Store Openings 12% 10% Estimated 8% 6% 3% Growth 4% 2% 0% 2007 2008 2009 2010 2011 New store openings include new and relocated stores © Copyright 2009 Walgreen Co. 11
  • 12. SG&A Growth Declining Ahead of Slowing Store Growth Store Added (including On-Site and 700 25% e Walgreen Rx Only stores) 600 20% 500 SG&A Growth Rate y 400 15% 300 10% ns 200 5% 100 es 0 0% FY99 FY00 FY01 FY02 FY03 FY04 FY05 FY06 FY07 FY08 FY09 Organic g Acquired q Adjusted for restructuring and restructuring-related costs © Copyright 2009 Walgreen Co. 12
  • 13. Reinventing the Customer Experience  4Q09 Milestones – Rolling out CCR in 400 Texas stores – Rolling out convenience offering of beer and wine – Re launched walgreens com Re-launched walgreens.com 2008 2009 2010 3Q09 – Apr/May Fall ’09 – Sep/Oct 09 Calendar 2010  35-store CCR pilot  CCR rollout in TX markets  CCR rollout nationwide  Category optimization  Begin beer and wine rollout  Loyalty initiative pilot  Inventory improvements  Re-launched Walgreens.com © Copyright 2009 Walgreen Co. 13
  • 14. the new walgreens com walgreens.com © Copyright 2009 Walgreen Co. 14
  • 15. Cost Reductions & Productivity Gains Year-over-Year Percent Increase 20% Gross Profit 15% SG&A 10% 5% 0% 2004 2005 2006 2007 2008 2009 SG&A adjusted for restructuring and restructuring-related costs in 1Q, 2Q, 3Q and 4Q 2009 Gross Profit adjusted for restructuring and restructuring-related costs in 2Q, 3Q, and 4Q 2009 © Copyright 2009 Walgreen Co. 15
  • 16. © Copyright 2009 Walgreen Co. 16
  • 17. 4Q and FY09 Financial Review Wade Miquelon Executive VP and CFO © Copyright 2009 Walgreen Co. 17
  • 18. Fourth Quarter Highlights 4Q08 4Q09 Net Sales 8.8% 7.6% Net Earnings 11.7% (1.5%) EPS (Diluted) $0.45 $0.44* Prescriptions Sales ($) 7.9% 9.0% Total Prescriptions (#) 4.9%** 9.1%** p Comparable Prescription Sales 2.0% 4.5% Front-end Sales 3.7% (1.4%) Total Sales 2.6% 2 6% 2.4% 2 4% Rx Scripts 1.1%*** 5.9%*** *Includes $.03 per share, diluted, of restructuring and restructuring-related costs. **Includes **I l d 111 b i 4Q08 and 136 b i 4Q09 positive i bp in d bp in iti impact d t more patients filli 90 d prescriptions t due to ti t filling 90-day i ti ***Includes 118 bp in 4Q08 and 179 bp in 4Q09 positive impact due to more patients filling 90-day prescriptions © Copyright 2009 Walgreen Co. 18
  • 19. Fiscal Year 2009 Highlights FY08 FY09 Net Sales 9.8% 7.3% Net Earnings 5.7% (7.0%) EPS (Diluted) $2.17 $2.02* Prescriptions Sales ($) 9.7% 7.8% Total Prescriptions (#) 6.4%** 6.9%** p Comparable Prescription Sales 3.9% 3.5% Front-end Sales 4.2% (0.5%) Total Sales 4.0% 4 0% 2.0% 2 0% Rx Scripts 2.8%*** 3.6%*** *Includes $.16 per diluted share, of restructuring and restructuring-related costs. **Includes **I l d 64 b i FY08 and 137 b i FY09 positive i bp in d bp in iti impact d t more patients filli 90 d prescriptions t due to ti t filling 90-day i ti ***Includes 75 bp in FY08 and 173 bp in FY09 positive impact due to more patients filling 90-day prescriptions © Copyright 2009 Walgreen Co. 19
  • 20. Gross Profit Margin 4Q08 4Q09 Change Gross Profit Margin 27.6% 27.7% +10 bps  Margin impacts + Positively impacted by retail pharmacy margins due to generics g - Partially offset by non-retail businesses, and lower FE margins d e to prod ct mi LIFO and due product mix, restructuring and restructuring-related costs © Copyright 2009 Walgreen Co. 20
  • 21. Percent Increase in SG&A Dollars Two-year Stacked 30% 28.0% 25.5% % 24.9% 25% 23.4% 10.0% 20% 11.2% 10.2% 8.0% 18.6% 16.9% 16 9% 17.6% 17 6% 15% 8.6% 14.1% 5.7% 7.4% 10% 6.1% 18.0% 18 0% 14.3% 14.7% 15.4% 5% 10.0% 11.2% 10.2% 8.0% 0% 1Q07 2Q07 3Q07 4Q07 1Q08 2Q08 3Q08 4Q08 +1Q08 +2Q08 +3Q08 +4Q08 +1Q09 +2Q09 +3Q09 +4Q09 Note: SG&A data adjusted for vacation accrual in 4Q08 and restructuring and restructuring-related costs in 1Q, 2Q, 3Q and 4Q 2009. © Copyright 2009 Walgreen Co. 21
  • 22. Rewire for Growth on Target  $500 million pre-tax savings in FY10  $1 billion pre-tax savings in FY11 1Q09 2Q09 3Q09 4Q09 Savings $.01 $.02 $.06 $.07 Costs* ($.01) ($.06) ($.06) ($.03) Net $.00 ($.04) $.00 $.04 Savings *Restructuring and restructuring-related charges include impact of CCR markdown activity on gross profit margin Restructuring © Copyright 2009 Walgreen Co. 22
  • 23. Income Statement Details 4Q08 4Q09 LIFO Provision $24M $48M g Restructuring $51M  SKU discontinuation $19M  Consultants and other $23M  Reduction in force $9M Net Interest Expense $7M $23M Tax Rate 37.1% 35.8% © Copyright 2009 Walgreen Co. 23
  • 24. Balance Sheet Highlights 4Q08 4Q09 Change Accounts Receivable $2.5B $2.5B (1.2%) Inventories $7.2B $6.8B ( (6.3%) ) Accounts Payable ($4.3B) ($4.3B) 0.4% Total $5.4B $5 4B $5.0B $5 0B (7.4%) (7 4%) Total as a % of Sales 37.0% 31.8% 14.1% © Copyright 2009 Walgreen Co. 24
  • 25. FIFO Inventory Trends 4Q08 1Q09 2Q09 3Q09 4Q09 Percent Change Total 7.2% 10.0% 4.6% (0.3%) (3.5%) Inventory I t Percent C Change Total g (2.2%) (2 2%) 0.1% 0 1% (4.0%) (4 0%) (9.1%) (9 1%) (11.1%) (11 1%) Inventory per Store* *Total FIFO inventory/total drugstore locations Total © Copyright 2009 Walgreen Co. 25
  • 26. Net Cash 1Q09 2Q09 3Q09 4Q09 Cash $886 $909 $2,300 $2,087 Short Term – $650 $100 $500 Investments Short Term Debt $1,081 $12 $10 $15 Long Term Debt $1,337 $2,332 $2,338 $2,336 Net Cash* ($1,532M) ($785M) $52M $236M *Net cash = cash and cash-equivalents plus short-term investments less short-term and long-term debt © Copyright 2009 Walgreen Co. 26
  • 27. Capital Expenditures Dollars in Billions FY08 FY09 FY10E New Stores $1.6 $1.4 lower Existing Stores $0.3 $0.2 higher DCs $0.1 $0 1 $0.1 $0 1 lower IT & Other $0.2 $0.2 higher Total T t l $2.2 $2 2 $1.9 $1 9 ~$1.6 $1 6 © Copyright 2009 Walgreen Co. 27
  • 28. Cash Flow ($ in Millions) Cash Flow from Operations Free Cash Flow (From St t (F Statements of Cash Flows) t f C h Fl ) (FCF=Cash Flow from Operations – C E ) (FCF C h Fl f O ti CapEx) 1,500 1,500 2009 1,000 1,000 2009 2008 500 500 2008 0 0 -500 -500 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q © Copyright 2009 Walgreen Co. 28
  • 29. The Road Ahead  Opportunities – Executing our 3 core strategies – Significant growth and share gain – Aggressively investing in business model  Challenges... Our Next Opportunities – Reimbursement pressure continues – Economic uncertainty © Copyright 2009 Walgreen Co. 29
  • 30. Questions & Answers Q ti A © Copyright 2009 Walgreen Co. 30
  • 31. © Copyright 2009 Walgreen Co. 31
  • 32. Appendix © Copyright 2009 Walgreen Co. 32
  • 33. Calculation of Adjusted SG&A: Restructuring Restr ct ring and Restructuring-Related Costs Restr ct ring Related Dollars in Millions 1Q08 1Q09 SGA under GAAP $ 3,193 $ 3,482 Less: Restructuring and g Restructuring-related Costs $ - $ 14 Adjusted SGA $ 3,193 $ 3,468 Adjusted YOY % Increase 8.6% © Copyright 2009 Walgreen Co. 33
  • 34. Calculation of Adjusted Gross Profit: Restructuring Restr ct ring and Restructuring-Related Costs Restr ct ring Related Dollars in Millions 2Q08 2Q09 Gross Profit under GAAP $ 4,442 $ 4,657 Plus: Restructuring and g Restructuring-related Costs $ - $ 11 Adjusted Gross Profit $ 4,442 $ 4,668 Adjusted YOY % Increase 5.1% © Copyright 2009 Walgreen Co. 34
  • 35. Calculation of Adjusted SG&A: Restructuring Restr ct ring and Restructuring-Related Costs Restr ct ring Related Dollars in Millions 2Q08 2Q09 SGA under GAAP $ 3,354 $ 3,627 Less: Restructuring and g Restructuring-related Costs $ - $ 82 Adjusted SGA $ 3,354 $ 3,545 Adjusted YOY % Increase 5.7% © Copyright 2009 Walgreen Co. 35
  • 36. Calculation of Adjusted Gross Profit: Restructuring Restr ct ring and Restructuring-Related Costs Restr ct ring Related Dollars in Millions 3Q08 3Q09 Gross Profit under GAAP $ 4,245 $ 4,459 Plus: Restructuring and g Restructuring-related Costs $ - $ 65 Adjusted Gross Profit $ 4,245 $ 4,524 Adjusted YOY % Increase 6.6% © Copyright 2009 Walgreen Co. 36
  • 37. Calculation of Adjusted SG&A: Restructuring Restr ct ring and Restructuring-Related Costs Restr ct ring Related Dollars in Millions 3Q08 3Q09 SGA under GAAP $ 3,331 $ 3,613 Less: Restructuring and g Restructuring-related Costs $ - $ 34 Adjusted SGA $ 3,331 $ 3,579 Adjusted YOY % Increase 7.4% © Copyright 2009 Walgreen Co. 37
  • 38. Calculation of Adjusted Gross Profit: Restructuring Restr ct ring and Restructuring-Related Costs Restr ct ring Related Dollars in Millions 4Q08 4Q09 Gross Profit under GAAP $ 4,035 $ 4,346 Plus: Restructuring and g Restructuring-related Costs $ - $ 19 Adjusted Gross Profit $ 4,035 $ 4,365 Adjusted YOY % Increase 8.2% © Copyright 2009 Walgreen Co. 38
  • 39. Calculation of Adjusted SG&A: Restructuring Restr ct ring and Restructuring-Related Costs Restr ct ring Related Dollars in Millions 4Q08 4Q09 SGA under GAAP $ 3,324 $ 3,644 Less: Restructuring and g Restructuring-related Costs $ - $ 32 Adjusted SGA $ 3,324 $ 3,612 Adjusted YOY % Increase 8.7% © Copyright 2009 Walgreen Co. 39
  • 40. Reconciliation of FIFO Inventory: 4Q08 1Q09 2Q09 3Q09 4Q09 Total FIFO $8,316.3 $9,408.4 $8,742.2 $8,082.4 $8,028.7 Inventory LIFO Provision $1,067.3 $1,110.5 $1,158.7 $1,191.4 $1,239.4 O Total LIFO $7,249.0 $7 249 0 $8,297.9 $8 297 9 $7,583.5 $7 583 5 $6,891.0 $6 891 0 $6,789.3 $6 789 3 Inventory © Copyright 2009 Walgreen Co. 40
  • 41. Calculation of Free Cash Flow: 1Q08 2Q08 3Q08 4Q08 1Q09 2Q09 3Q09 4Q09 Cash Flow from Operations $390 $1,116 $985 $548 $312 $1,428 $1,519 $852 under GAAP Capital Expenditures ($490) ($553) ($610) ($572) ($638) ($454) ($442) ($393) under GAAP Free Cash Flow non-GAAP ($100) $563 $375 ($24) ($326) $974 $1,077 $459 measure © Copyright 2009 Walgreen Co. 41